Peak Pharmaceuticals Won "The Most Brand Value Pharmaceutical Industry Enterprise" Again"
Release time:
2020-07-22
Jianfeng Pharmaceutical won the "Most Brand Value Pharmaceutical Industry Enterprise"
News 12# August 3 , the 10th Medical Observer Emerging Forum, the National Medical Elite Club Annual Meeting and the 2019 China Medical Emerging List Award Ceremony were held in Chongqing, peak Pharmaceutical Company won two awards, "2019 Most Brand Value Pharmaceutical Industry Enterprise Award" and "2019 Most Concerned Consistency Evaluation Variety Award.
Medical Observer Emerging Forum and National Medical Elite Club Annual Meeting are the annual ideological feast of China's pharmaceutical industry and have extensive influence in the industry. In this activity, the 2019 China Pharmaceutical New Sharp List and the 2019 Consistency Evaluation List were officially announced. With its rapid development in recent years, Jianfeng Pharmaceutical Co., Ltd. stood out in the selection of brand enterprises and won the "2019 Most Brand Value Pharmaceutical Industry Enterprise". Its product Berunning (Olopatadine Hydrochloride Eye Drops) won the "2019 Most Concerned Consistency Evaluation Variety Award".
2019 China Pharmaceutical New Profits List takes "media viewpoint and new perspective" as its conception and characteristics, focuses on the annual industry phenomenon-level highlights, makes a list of outstanding enterprises, products and pharmaceutical personnel with outstanding capital value in China's pharmaceutical industry during the year, and advocates enterprises to enhance their intrinsic value through continuous innovation, thus completing the value transition, therefore, it has attracted the extensive participation of the industry and the attention of the heavyweight media.
In this activity, "consistency evaluation varieties" are particularly concerned by the industry. The consistency evaluation of generic drugs makes generic drugs consistent with the original drugs in terms of quality and efficacy, and can replace the original drugs in clinical practice, which can not only save medical expenses, but also improve the quality of generic drugs in China and the overall development level of the pharmaceutical industry, so as to ensure the safe and effective use of drugs by the public. Berunning (olopatadine hydrochloride eye drops) introduced by Jianfeng Pharmaceutical in 2019 not only passed the consistency evaluation first, but also has the unique curative effect of antagonizing histamine H1- receptor and stabilizing mast cell bidirectional anti-allergy. It has good and fast curative effect on the treatment of allergic conjunctivitis in children, does not cause significant mast cell degranulation, so it is safer to use and has almost no adverse reaction to ocular tissues, it is an ideal drug for the treatment of allergic conjunctivitis, and has won the unanimous affirmation of experts and peers. (Fang Wentong Pan Jiacheng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page